NCT00099437 2026-03-18
CONFIRM
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT05654623 2026-03-18
VERITAC-2
Pfizer
Phase 3 Active not recruiting
NCT04191499 2026-03-17
INAVO120
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT02778685 2026-02-24
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT02763566 2026-02-05
MONARCH plus
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04576455 2026-01-16
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02107703 2025-10-21
MONARCH 2
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03147287 2025-09-30
Palbociclib After CDK and Endocrine Therapy (PACE)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03939897 2025-09-24
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02955394 2025-07-09
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
University of Colorado, Denver
Phase 2 Active not recruiting